229000.KQ
Gencurix Inc.
KOE · Healthcare · Medical - Specialties · KR
KRW 1,852.00
+0.11%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.9B | 7.5B | 5.1B | 2.6B | 2.6B |
| Cost of Revenue | 2.4B | 2.8B | 1.4B | 1.3B | 1.6B |
| Gross Profit | 6.5B | 4.8B | 3.8B | 1.3B | 945.4M |
| Operating Expenses | |||||
| R&D Expense | 2.7B | 3.4B | 4.2B | 4.5B | 4.2B |
| SG&A Expense | 6.5B | 4.6B | 3.1B | 2.8B | 2.5B |
| General & Admin Expense | 632.0M | 810.6M | 940.8M | 879.8M | 774.4M |
| Selling & Marketing Expense | 3.3B | 3.8B | 2.1B | 1.9B | 1.7B |
| Other Expenses | 5.1B | 4.1B | 5.0B | 5.2B | (41.2M) |
| Total Operating Expenses | 13.7B | 12.1B | 12.3B | 12.5B | 12.4B |
| Cost and Expenses | 15.5B | 14.9B | 13.7B | 13.8B | 14.0B |
| Operating Income (EBIT) | (7.2B) | (7.4B) | (8.5B) | (12.4B) | (11.4B) |
| Non-Operating | |||||
| Interest Income | 128.5M | 110.3M | 70.7M | 260.3M | 198.4M |
| Interest Expense | 796.2M | 721.6M | 767.0M | 810.7M | 478.2M |
| Net Interest Income | (667.7M) | (611.4M) | (696.3M) | (550.7M) | (279.8M) |
| Other Non-Op Income/Expense | (61.1M) | 237.7M | 4.4B | (7.9B) | (14.4B) |
| Non-Operating Income (excl Interest) | 20.1M | — | (5.2B) | 7.1B | 13.9B |
| EBT (Pre-Tax Income) | (7.3B) | (7.1B) | (4.1B) | (20.3B) | (25.3B) |
| Income Tax Expense | 233.5M | 268.4M | 10.6M | (155.3M) | (649.9K) |
| Bottom Line | |||||
| Net Income | (7.5B) | (7.4B) | (4.1B) | (19.3B) | (24.6B) |
| Earnings from Cont. Ops | (7.5B) | (7.4B) | (4.1B) | (20.1B) | (25.5B) |
| Earnings from Discont. Ops | — | — | — | — | (750.00) |
| Bottom Line Net Income | (7.5B) | (7.4B) | (4.1B) | (19.3B) | (24.6B) |
| Per Share | |||||
| Basic EPS | (₩395) | (₩462) | (₩275) | (₩1,629) | (₩3,310) |
| Diluted EPS | (₩395) | (₩462) | (₩275) | (₩1,629) | (₩3,310) |
| Revenue Per Share | ₩381 | ₩468 | ₩347 | ₩220 | ₩344 |
| Shares | |||||
| Basic Shares Outstanding | 23.4M | 16.1M | 14.8M | 11.8M | 7.4M |
| Diluted Shares Outstanding | 23.4M | 16.1M | 14.8M | 11.8M | 7.4M |
| Profitability Metrics | |||||
| EBITDA | (5.6B) | (6.0B) | (1.9B) | (18.1B) | (23.9B) |
| D&A | 1.3B | 1.4B | 1.5B | 1.4B | 915.1M |
| EBIT | (7.4B) | (7.4B) | (3.4B) | (19.5B) | (24.9B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026